Rather than being a negative trait, a VC firm's "power"—its network and ability to influence outcomes—is a critical service for founders. Entrepreneurs have great ideas but lack access. The VC's role is to provide that power to open doors for sales, policy, and partnerships, acting as a force multiplier.

Venture capitalists have their own fundraising pressures and obligations to their LPs. Founders who understand that VCs need to generate returns to raise their next fund can build a more strategic and aligned relationship. This empathy helps in navigating milestone discussions and exit strategies, moving beyond a simple capital provider-recipient dynamic.

Beyond accelerators, pure investors, and traditional company builders, this new VC model provides "hardcore primary data generation drug making support." It involves a team of 10+ experts engaging with a startup multiple times per day, offering an intensity of operational involvement that other models lack.

The abundance of capital has shifted the VC mindset from serving founders over a decade to simply "winning" the next hot deal. This transactional approach is misaligned with what founders truly need: a committed, long-term partner who puts the company first.

Instead of traditional pitching, TurboPuffer's CEO maintains a spreadsheet ranking potential investors on a 'tier list.' VCs earn their spot on the cap table by providing tangible value—like customer intros or strategic advice—long before a deal is discussed. This value-first approach ensures the cap table is composed of active partners.

Unlike venture creation firms that generate ideas internally, Curie.bio operates on a 'Freedom for Founders' principle. It believes the best ideas come from external innovators and its role is to augment them with capital-efficient support, fractional expertise, and operational help to translate those ideas into companies.

By defining the entrepreneur as the primary customer, a VC firm changes its entire operating model. This customer-centric view informs decisions on partner incentives (removing attribution), community building, and support services. The result is a powerful brand that attracts the best founders and generates high-fidelity deal flow through referrals.

The biotech venture model is built on syndication, not competition. As a drug progresses, capital requirements balloon to hundreds of millions for late-stage trials, far exceeding any single VC's capacity. This structural reality forces firms to co-invest and partner throughout a company's lifecycle.

For pre-revenue biotechs like Voyager, partnering provides non-dilutive capital. More importantly, it de-risks development by sharing costs and leveraging a larger company's resources and expertise. This can increase a drug's probability of success, a crucial factor when most programs fail.